CONSUN PHARMACEUTICAL GROUP (CONSUN PHARMA) has published its 10th Environmental, Social and Governance (ESG) Report, covering the 2025 financial year and approved by the board on 26 March 2026.

Governance and Compliance • The board-led ESG framework now includes an ESG Committee and Working Group; 30 senior executives completed specialised ESG training in 2025. • Anti-corruption measures feature 39 compliance training sessions reaching 1,606 employees; no corruption cases were reported. • Hong Kong Quality Assurance Agency provided limited assurance, confirming reporting in line with HKEX ESG Code.

Environmental Performance and Targets • Total Scope 1 emissions fell to 7,132.86 tCO₂e (2024: 12,602.63 t) while Scope 2 emissions were 23,990.59 tCO₂e (2024: 19,948.67 t). • Energy use dropped to 77,770.40 MWh (-7.7% YoY); coal use ended as the Group completed “coal-to-gas” conversion. • Water consumption decreased 6.9% to 394,946 t. • Targets set: cut Scope 1 intensity 10% and Scope 2 intensity 20% by 2030 (base year 2023); operational carbon neutrality aimed for 2060. • Yulin subsidiary generated 0.59 GWh of solar power in its first year of photovoltaic operation.

Product Quality and Supply Chain • All production lines maintain GMP certification; 19 regulatory inspections in 2025 achieved 100% pass rate. • No product recalls; 41 consumer complaints were fully resolved. • Supplier base totals 743, managed under a full-lifecycle audit system; green procurement guidelines implemented.

Innovation and Intellectual Property • R&D pipeline comprises 25 projects; SK-08 and SK-09 received China and US clinical approvals. • Post-doctoral workstation and seven R&D platforms support nearly 100 researchers; over 70 SCI papers published to date. • The Group holds more than 50 valid patents, including 13 international filings.

Human Capital • Workforce stands at 3,115 employees; females account for 47%. • Training reached 127,515 hours, averaging 41 hours per employee. • Six work-related incidents resulted in 304 lost days; corrective measures implemented.

Community Investment and Brand Value • Charitable donations totalled RMB 6.02 million. • The “Uremic Clearance Granule” and “Bone-Setting Liquid” brands garnered multiple industry awards. • Independent valuation placed the CONSUN brand at RMB 14.76 billion, again ranking among “China’s 500 Most Valuable Brands.”